Needham Reiterates Buy Rating on Neurocrine Biosciences, Sets $204 Target
Needham reiterated its Buy rating on Neurocrine Biosciences and maintained a $204 price target. The target implies 49.0% upside from the Oct. 15 close of $136.95.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.